Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.71, delivering a surprise of -7.58%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Nurix Therapeutics, which belon ...